Entity

Time filter

Source Type

Cleveland, OH, United States

Meyers J.D.,Case Western Reserve University | Meyers J.D.,MIM Software Inc. | Cheng Y.,Case Western Reserve University | Cheng Y.,University of Chicago | And 9 more authors.
Particle and Particle Systems Characterization | Year: 2015

Targeted drug delivery using epidermal growth factor peptide-targeted gold nanoparticles (EGFpep-Au NPs) is investigated as a novel approach for delivery of photodynamic therapy (PDT) agents, specifically Pc 4, to cancer. In vitro studies of PDT show that EGFpep-Au NP-Pc 4 is twofold better at killing tumor cells than free Pc 4 after increasing localization in early endosomes. In vivo studies show that targeting with EGFpep-Au NP-Pc 4 improves accumulation of fluorescence of Pc 4 in subcutaneous tumors by greater than threefold compared with untargeted Au NPs. Targeted drug delivery and treatment success can be imaged via the intrinsic fluorescence of the PDT drug Pc 4. Using Pc 4 fluorescence, it is demonstrated in vivo that EGFpep-Au NP-Pc 4 impacts biodistribution of the NPs by decreasing the initial uptake by the reticuloendothelial system (RES) and by increasing the amount of Au NPs circulating in the blood 4 h after IV injection. Interestingly, in vivo PDT with EGFpep-Au NP-Pc 4 results in interrupted tumor growth when compared with EGFpep-Au NP control mice when selectively activated with light. These data demonstrate that EGFpep-Au NP-Pc 4 utilizes cancer-specific biomarkers to improve drug delivery and therapeutic efficacy over untargeted drug delivery. Gold nanoparticles, as delivery vehicles for hydrophobic photodynamic therapy drugs, allow for specialized targeting and delivery to cancer cells for improved therapeutic efficacy. The EGF receptor-targeted gold nanoparticles bind to receptors long enough on cancer cell surfaces to deliver their therapeutic payload into cancer cells without requiring internalization of the entire delivery vehicle. © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.


Oborski M.J.,University of Pittsburgh | Laymon C.M.,University of Pittsburgh | Qian Y.,University of Pittsburgh | Lieberman F.S.,University of Pittsburgh | And 2 more authors.
Translational Oncology | Year: 2014

Evaluation of cancer-therapy efficacy at early time points is necessary for realizing the goal of delivering maximally effective treatment. Molecular imaging with carefully selected tracers and methodologies can provide the means for realizing this ability. Many therapies are aimed at inducing apoptosis in malignant tissue; thus, the ability to quantify apoptosis in vivo may be a fruitful approach. Apoptosis rate changes occur on a fast time scale, potentially allowing correspondingly rapid decisions regarding therapy value. However, quantification of tissue status based on apoptosis imaging is complicated by this time scale and by the spatial heterogeneity of the process. Using the positron emission tomography (PET) tracer 2-(5-fluoro-pentyl)-2-methyl-malonic acid (F-18 ML-10), we present methods of voxelwise analysis yielding quantitative measures of apoptosis changes, parametric apoptosis change images, and graphical representation of apoptotic features. A method of deformable registration to account for anatomic changes between scan time points is also demonstrated. Overall apoptotic rates deduced from imaging depend on tumor density and the specific rate of apoptosis, a situation resulting in an ambiguity in the source of observed image-based changes. The ambiguity may be resolved through multimodality imaging. An example of intracellular sodium magnetic resonance imaging coupled with F-18 ML-10 PET is provided. © 2014 Neoplasia Press, Inc. All rights reserved.


Patent
Mim Software Inc. | Date: 2013-03-15

A registration technique is provided that can combine one or more related registrations to enhance accuracy of a registration of image volumes. A registration relationship between a first source volume and a target volume and a registration relationship between the first source volume and a second source volume are concatenated to provide an estimate of a registration relationship between the second source volume and the target volume. The estimate is utilized to inform the direct registration of the second source volume to the target volume or utilized in place of the direct registration.


Mim

Trademark
MIM Software Inc and MIMvista Corporation | Date: 2005-09-20

Computer software for the use of medical image processing in Radiology.


Trademark
Mim Software Inc. and MIMvista Corporation | Date: 2007-09-18

Computer software for use in medical image processing in the field of radiology.

Discover hidden collaborations